Information  X 
Enter a valid email address

Company Name matching 'Biogen Inc'

Date
Time Source
Company
Announcement
03 Dec 2019 12:30 pm GNW Factsheet Biogen Inc. (0R1B) Biogen Announces Positive Phase 2 Study Results for Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE)
22 Nov 2019 12:30 pm GNW Factsheet Biogen Inc. (0R1B) Biogen Presents Data Demonstrating Improved Gastrointestinal Tolerability With VUMERITY™ (diroximel fumarate) Compared to TECFIDERA® (dimethyl fumarate)
21 Nov 2019 12:30 pm GNW Factsheet Biogen Inc. (0R1B) Biogen Announces Enrollment Completion of Global Phase 3 Gene Therapy Study for an Inherited Retinal Disorder
06 Nov 2019 12:30 pm GNW Factsheet Biogen Inc. (0R1B) Biogen to Expand Biosimilars Portfolio and Gain Access to Additional Markets Through New Transaction with Samsung Bioepis
04 Nov 2019 9:30 pm GNW Factsheet Biogen Inc. (0R1B) Biogen to Host Investor Webcasts from Clinical Trials on Alzheimer’s Disease (CTAD) Congress on December 5, 2019
30 Oct 2019 11:30 am GNW Factsheet Biogen Inc. (0R1B) Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis
22 Oct 2019 11:30 am GNW Factsheet Biogen Inc. (0R1B) Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies
21 Oct 2019 12:30 pm GNW Factsheet Biogen Inc. (0R1B) Biogen and Samsung Bioepis to Present Data for Infliximab and Adalimumab Biosimilars at United European Gastroenterology Week
02 Oct 2019 12:30 pm GNW Factsheet Biogen Inc. (0R1B) Landmark NURTURE Study of Infants with Spinal Muscular Atrophy (SMA) Treated Pre-Symptomatically with SPINRAZA® (nusinersen) Published in Neuromuscular Disorders
01 Oct 2019 1:00 pm GNW Factsheet Biogen Inc. (0R1B) Biogen Announces Leadership Update
23 Sep 2019 8:00 am GNW Factsheet Biogen Inc. (0R1B) Interferon Beta Treatments, Including PLEGRIDY® (peginterferon beta-1a) and AVONEX® (interferon beta-1a), Receive Positive CHMP Opinion for Use During Pregnancy and Breastfeeding
18 Sep 2019 12:30 pm GNW Factsheet Biogen Inc. (0R1B) Biogen Advances Spinal Muscular Atrophy (SMA) Clinical Research with New Study Evaluating a Higher Dose of SPINRAZA® (nusinersen) and Additional Data in a Broad Range of Patients
17 Sep 2019 12:30 pm GNW Factsheet Biogen Inc. (0R1B) Biogen Ranked #1 Biotechnology Company on Dow Jones Sustainability World Index
12 Sep 2019 10:00 am GNW Factsheet Biogen Inc. (0R1B) New Research Demonstrate Biogen’s Continued Commitment to Improve Care of Patients with Multiple Sclerosis Across Treatment Spectrum
11 Sep 2019 10:00 am GNW Factsheet Biogen Inc. (0R1B) New Data Presented at ECTRIMS Reinforce Long-term Benefits of TECFIDERA® (dimethyl fumarate) Over 10 Years
30 Jul 2019 12:30 pm GNW Factsheet Biogen Inc. (0R1B) Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared to Dimethyl Fumarate in Patients with Multiple Sclerosis
01 Jul 2019 12:30 pm GNW Factsheet Biogen Inc. (0R1B) Biogen Announces New Data Further Establishing SPINRAZA® (nusinersen) as a Foundation of Care in Spinal Muscular Atrophy for a Broad Range of Patients
29 Jun 2019 9:00 am GNW Factsheet Biogen Inc. (0R1B) Biogen announces European label update for SPINRAZA (nusinersen) which includes longer-term data across a broad range of ages and types of Spinal Muscular Atrophy
12 Jun 2019 12:05 am GNW Factsheet Biogen Inc. (0R1B) Biogen to Present New Safety and Efficacy Data on Biosimilars and Estimates 1.8 Billion Euros in Savings for the European Healthcare System in 2019
07 Jun 2019 10:41 am GNW Factsheet Biogen Inc. (0R1B) Biogen Completes Acquisition of Nightstar Therapeutics for Approximately $800 Million
30 May 2019 12:30 pm GNW Factsheet Biogen Inc. (0R1B) New Phase 3 Interim Results Support Safety and Efficacy of Diroximel Fumarate in Multiple Sclerosis
20 May 2019 12:30 pm GNW Factsheet Biogen Inc. (0R1B) Biogen Recommends Stockholders Reject the Below-market Mini-tender Offer by TRC Capital Corporation
15 May 2019 12:02 am GNW Factsheet Biogen Inc. (0R1B) Biogen’s SPINRAZA® (nusinersen) Receives Positive Recommendation from NICE for Funding in the United Kingdom for the Treatment of Infants, Children and Adults with Spinal Muscular Atrophy
07 May 2019 12:30 pm GNW Factsheet Biogen Inc. (0R1B) Data at AAN Demonstrate Biogen’s Leadership and Commitment to Innovation in MS
06 May 2019 12:30 pm GNW Factsheet Biogen Inc. (0R1B) Biogen Presents Data at 2019 AAN Annual Meeting Affirming Longer-Term Safety and Durability of Treatment with SPINRAZA® (nusinersen)
01 May 2019 9:30 pm GNW Factsheet Biogen Inc. (0R1B) Biogen to Present New Interim Data from Its Phase 1/2 Clinical Study of Tofersen (BIIB067) for the Potential Treatment of a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS)
  12:30 pm GNW Factsheet Biogen Inc. (0R1B) Biogen To Present Data At AAN Highlighting Its Innovative Marketed Treatments And Investigational Pipeline Programs For Complex Neurodegenerative Diseases
30 Apr 2019 12:33 pm GNW Factsheet Biogen Inc. (0R1B) Data Published in Neurology Show that Treatment with SPINRAZA® (nusinersen) Improved Motor Function and Provided Long-Term Benefit for Individuals with Later-Onset Spinal Muscular Atrophy
29 Apr 2019 12:30 pm GNW Factsheet Biogen Inc. (0R1B) Biogen Announces Three New Nominees for Election to Board of Directors
12 Apr 2019 12:30 pm GNW Factsheet Biogen Inc. (0R1B) Biogen Continues to Advance Innovation in SMA with New Data in Adults and Infants to Be Presented at MDA Clinical and Scientific Conference
21 Mar 2019 11:00 am GNW Factsheet Biogen Inc. (0R1B) Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer’s Disease
12 Mar 2019 7:00 am GNW Factsheet Biogen Inc. (0R1B) Biogen Enters Into an Agreement to Sell Its Large-Scale Biologics Manufacturing Site in Hillerød, Denmark to Fujifilm
04 Mar 2019 7:00 am GNW Factsheet Biogen Inc. (0R1B) Biogen Announces Agreement to Acquire Nightstar Therapeutics to Establish Clinical Pipeline of Gene Therapy Candidates in Ophthalmology
28 Feb 2019 12:30 pm GNW Factsheet Biogen Inc. (0R1B) Biogen Further Expands Presence in China with Approval of SPINRAZA® (nusinersen), the First and Only Treatment for Spinal Muscular Atrophy
25 Feb 2019 12:30 pm GNW Factsheet Biogen Inc. (0R1B) Alkermes and Biogen Announce U.S. Food and Drug Administration Acceptance of Diroximel Fumarate New Drug Application for Multiple Sclerosis
04 Jan 2019 12:30 pm GNW Factsheet Biogen Inc. (0R1B) Biogen and Skyhawk Therapeutics Announce Agreement to Develop Novel Small Molecule RNA Splicing Modifiers for Neurological Disease Targets
03 Jan 2019 12:30 pm GNW Factsheet Biogen Inc. (0R1B) First Patient Enrolled in Biogen’s Phase 3b Study to Evaluate Extended Interval Dosing (EID) with Natalizumab in Multiple Sclerosis
17 Dec 2018 12:30 pm GNW Factsheet Biogen Inc.; Alkermes plc (0R1B) Alkermes and Biogen Announce Submission of a New Drug Application to U.S. Food and Drug Administration for Diroximel Fumarate in Multiple Sclerosis
06 Dec 2018 12:30 pm GNW Factsheet Biogen Inc.; Ionis Pharmaceuti (0R1B) Biogen Exercises Option with Ionis to Develop and Commercialize Investigational Treatment BIIB067 for a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS) Based on Positive Phase 1 Data
29 Nov 2018 12:30 pm GNW Factsheet Biogen Inc. (0R1B) International Prix Galien Recognizes SPINRAZA® as Best Biotechnology Product
26 Oct 2018 2:15 pm GNW Factsheet Biogen Inc. (0R1B) Biogen and Eisai Announce Presentation of Detailed Analyses from the Phase 1b Long-Term Extension Study of Aducanumab at Clinical Trials on Alzheimer’s Disease (CTAD)
25 Oct 2018 1:31 pm GNW Factsheet Biogen Inc. (0R1B) Eisai and Biogen Announce Presentation of Additional Data From the Phase II Clinical Trial of BAN2401 in Early Alzheimer’s Disease at the 2018 Clinical Trials on Alzheimer’s Disease (CTAD) Conference
23 Oct 2018 6:00 am GNW Factsheet Biogen Inc.; UCB (0R1B) UCB and Biogen Announce Topline Results from a Phase 2b Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus
18 Oct 2018 12:30 pm GNW Factsheet Biogen Inc. (0R1B) Biogen to Present Data from Alzheimer’s Disease Portfolio at the 2018 Clinical Trials on Alzheimer’s Disease (CTAD) Meeting
17 Oct 2018 7:00 am GNW Factsheet Biogen Inc. (0R1B) IMRALDI™, Biogen’s Adalimumab Biosimilar Referencing Humira®, Is Launched in the European Union
11 Oct 2018 12:30 pm GNW Factsheet Biogen Inc. (0R1B) Biogen Advances Research to Improve Outcomes for Patients With Multiple Sclerosis
06 Oct 2018 12:30 pm GNW Factsheet Biogen Inc. (0R1B) New SPINRAZA® (nusinersen) Data Presented at Annual Congress of the World Muscle Society Demonstrate Benefits in Treating Presymptomatic Infants with Spinal Muscular Atrophy
03 Oct 2018 12:30 pm GNW Factsheet Biogen Inc. (0R1B) Biogen to Present Data from its Neurology Pipeline at the 2018 International Congress of Parkinson’s Disease and Movement Disorders (MDS)
02 Oct 2018 12:30 pm GNW Factsheet Biogen Inc. (0R1B) Biogen Highlights at ECTRIMS 2018 Data on Its Industry-Leading Multiple Sclerosis Portfolio and a Range of Initiatives Aimed at Transforming Patient Care
04 Sep 2018 12:30 pm GNW Factsheet Biogen Inc. (0R1B) Biogen Enrolls First Patient in Global Phase 3 Study of BIIB093 (IV Glibenclamide) for Large Hemispheric Infarction
28 Aug 2018 12:30 pm GNW Factsheet Biogen Inc. (0R1B) Biogen and Eisai Report Data from Long-Term Extension Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab
25 Jul 2018 10:08 pm GNW Factsheet Biogen Inc. (0R1B) Eisai and Biogen Announce Detailed Results of Phase II Clinical Study of BAN2401 in Early Alzheimer's Disease at Alzheimer's Association International Conference (AAIC) 2018
  3:30 pm GNW Factsheet Biogen Inc. (0R1B) Eisai and Biogen Present Detailed Results From Phase II Clinical Study of Elenbecestat in MCI and Mild to Moderate Alzheimer's Disease at Alzheimer's Association International Conference (AAIC) 2018
18 Jul 2018 12:30 pm GNW Factsheet Biogen Inc. (0R1B) Data to be Presented From Biogen's Alzheimer's Disease Clinical Development Portfolio at the 2018 Alzheimer's Association International Conference (AAIC)
06 Jul 2018 12:30 am GNW Factsheet Biogen Inc. (0R1B) Eisai and Biogen Announce Positive Topline Results of the Final Analysis for BAN2401 at 18 Months
28 Jun 2018 9:06 pm GNW Factsheet Biogen Inc. (0R1B) Biogen Exercises Option to Increase Ownership in Samsung Bioepis
13 Jun 2018 12:30 pm GNW Factsheet Biogen Inc. (0R1B) Biogen Enhances Commitment to SMA Research with Data Presented at Annual SMA Conference
07 Jun 2018 12:30 pm GNW Factsheet Biogen Inc. (0R1B) Biogen Enters Exclusive Option Agreement to Acquire TMS' Phase 2 Asset for Acute Stroke
31 May 2018 12:30 pm GNW Factsheet Biogen Inc. (0R1B) Biogen Appoints Daniel Karp as EVP, Corporate Development


Company Announcements Archive »

 
Headlines
Top categories
Company finder
Forthcoming announcements

a d v e r t i s e m e n t